Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Hansoh Pharmaceutical Group Co's EV-to-EBIT for today is
Hansoh Pharmaceutical Group Co's current Enterprise Value is $19,744 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $920 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Hansoh Pharmaceutical Group Co's EV-to-EBITDA for today is:
Hansoh Pharmaceutical Group Co's current Enterprise Value is $19,744 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $976 Mil.
Hansoh Pharmaceutical Group Co's current Enterprise Value is $19,744 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $2,114 Mil.
Hansoh Pharmaceutical Group Co's current Enterprise Value is $19,744 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $947 Mil.
Hansoh Pharmaceutical Group Co's current Enterprise Value is $19,744 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $878 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Enterprise Value Related Terms
Hansoh Pharmaceutical Group Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Enterprise Value Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Enterprise Value falls into.
Hansoh Pharmaceutical Group Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HNSPF) has a Enterprise Value of $19,744 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Hansoh Pharmaceutical Group Co and its competitors.
Is Hansoh Pharmaceutical Group Co's Enterprise Value too high?
Hansoh Pharmaceutical Group Co's current Enterprise Value is $19,744 Mil. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Enterprise Value compare to ZTS and UTHR?
Hansoh Pharmaceutical Group Co's Enterprise Value of $19,744 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Hansoh Pharmaceutical Group Co and its competitors. Hansoh Pharmaceutical Group Co's current Enterprise Value is $19,744 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $3.83 — trading 27.5% above its estimated fair value. The current Enterprise Value is $19,744 Mil. Hansoh Pharmaceutical Group Co's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Enterprise Value is $19,744 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 27.5% above its estimated GF Value™ of $3.00.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
Enterprise Value: $19,744 Mil
GF Value™: $3.00 vs. price of $3.83 (27.5% above fair value)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
90GF Score
Get the complete analysis for HNSPF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
